Clinical Trial: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia

This study has been suspended.

Sponsors and Collaborators: Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)


RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill leukemia cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation and interleukin-2 in treating patients who have acute leukemia.

Condition Treatment or Intervention Phase
adult acute lymphoblastic leukemia
adult acute myeloid leukemia
childhood acute lymphoblastic leukemia
childhood acute myeloid leukemia
secondary acute myeloid leukemia
 Drug: busulfan
 Drug: cyclophosphamide
 Drug: etoposide
 Drug: filgrastim
 Drug: interleukin-2
 Drug: melphalan
 Procedure: biological response modifier therapy
 Procedure: bone marrow ablation with stem cell support
 Procedure: chemotherapy
 Procedure: colony-stimulating factor therapy
 Procedure: cytokine therapy
 Procedure: interleukin therapy
 Procedure: peripheral blood stem cell transplantation
Phase II

MedlinePlus related topics:  Bone Marrow Diseases;   Immune System and Disorders;   Leukemia, Adult Acute;   Leukemia, Adult Chronic;   Leukemia, Childhood;   Lymphatic Diseases

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Study of Busulfan, Cyclophosphamide, and Etoposide Followed By Autologous Peripheral Blood Stem Cell Transplantation and Interleukin-2 in Patients With High-Risk Acute Leukemia

Further Study Details: 


OUTLINE: Following a course of mobilization chemotherapy, patients receive priming therapy comprising filgrastim (G-CSF) and interleukin-2 through the completion of leukapheresis. Patients then receive oral busulfan 4 times daily on days -8 through -5, cyclophosphamide IV continuously on days -4 and -3, and etoposide IV over 2 hours on day -4. For patients unable to receive cyclophosphamide and etoposide, melphalan IV is administered instead on days -3 and -2. Autologous peripheral blood stem cells (PBSC) are reinfused on day 0.

Patients then receive G-CSF daily beginning on day 0 and continuing until blood counts recover followed by interleukin-2 subcutaneously daily beginning at the completion of G-CSF therapy and continuing for 6 months.

Patients are followed weekly for 1 month and then monthly thereafter.

PROJECTED ACCRUAL: A total of 19-25 patients will be accrued for this study within 3-5 years.


Genders Eligible for Study:  Both



  • Histologically or cytologically confirmed acute leukemia
  • High-risk due to any of the following:
  • Cytogenetic abnormalities involving 5q, 7q, 8q, 11q23, or t(9;22)
  • WBC greater than 100,000/mm3
  • Prior myelodysplastic syndrome
  • Complete remission (CR) lasting less than 12 months
  • No favorable cytogenetic parameters (e.g., t(15;17), inv16, or t(8;21))
  • CR following standard anti-leukemic therapy confirmed by bone marrow evaluation
  • Second and third CR allowed
  • Ineligible for higher priority national or institutional study or allogeneic peripheral blood stem cell transplantation


  • Any age

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • See Disease Characteristics


  • Bilirubin less than 1.5 times normal
  • SGOT or SGPT less than 1.5 times normal


  • Creatinine less than 1.5 times normal


  • LVEF at least 45% if receiving cyclophosphamide
  • Normal electrocardiogram OR
  • Approval by cardiologist


  • DLCO less than 60% predicted OR
  • Approval by pulmonologist


  • Not pregnant or nursing
  • No concurrent illness that would preclude study


  • Not specified


  • Not specified

Endocrine therapy

  • Not specified


  • Not specified


  • Not specified

Location Information

New York
      Herbert Irving Comprehensive Cancer Center at Columbia University, New York,  New York,  10032,  United States

Study chairs or principal investigators

Charles S. Hesdorffer, MD,  Study Chair,  Columbia Presbyterian Medical Center   

More Information

Study ID Numbers:  CDR0000068386; CPMC-IRB-8872; CPMC-CAMP-27; NCI-G00-1889
Record last reviewed:  February 2004
Last Updated:  October 13, 2004
Record first received:  January 6, 2001 Identifier:  NCT00008190
Health Authority: Unspecified processed this record on 2005-04-08

Cache Date: April 9, 2005